Updates in the Management of Primary Mediastinal B Cell Lymphoma

Clin Lymphoma Myeloma Leuk. 2023 Aug 21:S2152-2650(23)00274-4. doi: 10.1016/j.clml.2023.08.014. Online ahead of print.ABSTRACTPrimary mediastinal B cell lymphoma (PMBCL) is considered a distinct pathology according to the WHO classification of lymphoid malignancies. Patients have a better prognosis after the addition of Rituximab to anthracycline-based chemotherapy. The role of consolidative radiotherapy is controversial after the approval of dose-adjusted R-EPOCH and the selection of patients to undergo radiotherapy is based on end-of-therapy PET CT. In the relapsed/refractory setting, new approved drugs and other under investigation have improved patient outcomes. This review summarizes the different treatment modalities in (PMBCL) in the frontline and the relapsed/refractory settings.PMID:37722943 | DOI:10.1016/j.clml.2023.08.014
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research